CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
癌症免疫治疗的最新进展：聚焦于 FDA 批准的疫苗和基于新抗原的疫苗
英文原题：Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.
查看英文原题
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫疗法是指重新训练免疫系统以靶向恶性细胞的概念。现有的免疫治疗选择多种多样，包括免疫调节抗体、免疫刺激细胞因子、CAR-T 细胞疗法和疫苗。总体而言，随着对肿瘤微环境、免疫通路和生物技术知识的不断扩展，该领域发展迅速。具体而言，新抗原的鉴定、表征以及配制成疫苗方面的进展展现出良好前景。本综述聚焦于既往美国食品药品监督管理局批准的癌症治疗性疫苗和新抗原疫苗的开发进展，以及相关的临床试验。
展开英文摘要原文
Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines.
Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise. This review is focused on previously United States Food and Drug Administration-approved cancer therapeutic vaccines and neoantigen-based vaccine developments along with the associated relevant clinical trials.
论文信息
- 作者
- Hargrave A、Mustafa AS、Hanif A、Tunio JH、Hanif SNM
- 单位
- Department of Biomedical Sciences, University of Pikeville, Pikeville, KY 41501, USA.United States
- 文献类型
- 综述
- 期刊
- Vaccines2023 Oct 25
- 原文标识
- PubMed 38005965 · DOI 10.3390/vaccines11111633
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →